Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate
This article was originally published in The Pink Sheet
US federal court judge says Mucinex marketer Reckitt Benckiser is not responsible for OTC private label competitor Aurobindo’s attorney fees because its patent infringement complaint was not “exceptional” and its argument had merit. The decision could bolster drug firms' confidence in defending their patents.
You may also be interested in...
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.
L’Oreal Joins Heavyweights Tackling Sustainable Surfactants With Geno Biotech
L’Oreal, Kao and Unilever have partnered with Genomatica, Inc. (Geno) to develop sustainable surfactants by replacing feedstocks such as palm oil and fossil fuels with biotech alternatives.
Clinique, Living Proof Expand Beautyverse With New Virtual Reality E-Commerce Experiences
“The Clinique Lab is the next generation of digital innovation,” says The Estee Lauder Companies brand of its three-dimensional online dreamscape where users’ customized avatars can learn about the brand, its products and ingredients, unlock exclusive offers, and browse a virtual shop. Unilever’s Living Proof announced the launch of a similar concept this month as beauty’s presence in the metaverse grows.